医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Simavita Receives ITAC Award for “Growing an IT Company Overseas”

2015年11月27日 PM04:30
このエントリーをはてなブックマークに追加


 

SYDNEY

Simavita Limited (TSX-V:SV)(ASX:SVA), a global leader in the digital healthcare sector, is delighted to announce that it received the “Growing an IT company Overseas” award at this week’s annual Information Technology in Aged Care (ITAC) conference. The ITAC conference is the Australian aged care industry’s pre-eminent annual event for technology solutions.

The award recognises Simavita’s program to drive penetration of its Smart Incontinence Management (SIM™) system into the global digital healthcare market.

Simavita CEO, Philippa Lewis commented, “Breaking into foreign regions with a digital healthcare platform is rare, so we are very excited that Simavita’s efforts are being recognised by our peers in the Australian digital healthcare space. We are starting to see the evidence of early stage traction from our work and this award acknowledges the momentum building offshore around SIM™ as we push hard to drive our Australian developed technology into other markets.”

For further information, see our website (www.simavita.com) or contact the persons outlined below.

About Simavita

Simavita is a digital healthcare company that has developed an innovative software platform. The first application for the platform is a world first solution for the management of urinary incontinence, with a focus on the elderly. This platform technology is an instrumented incontinence assessment application that provides evidence-based incontinence management care plans to the residential aged care market.

About SIM™

SIM™ is a wireless sensor technology that delivers evidence-based instrument incontinence data on individuals. SIM™ provides user friendly tools and software to assess the incontinence condition and to help plan better outcomes. SIM™ is used to detect, record and report incontinence events during a compulsory or recommended assessment period in residential aged care facilities to develop an evidence-based incontinence care plan.

Conducting assessments is mandatory in many countries and the incontinence assessment creates an influential element of care of each individual. For more information on Simavita or SIM™, please visit www.simavita.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151126005553/en/

CONTACT

Company
Simavita Limited
Philippa Lewis, +61 2 8405 6381
Chief
Executive Officer
Thomas Howitt, + 61 418 351 127
Chief
Financial Officer
or
Media and Investor Relations
Jane
Lowe, +61 411 117 774
jane.lowe@irdepartment.com.au

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险
  • ダウン症候群の小児を対象とする睡眠時障害診断のマルチチャンネル研究に先立つ閉塞性睡眠時無呼吸症リスクのスクリーニングとしてMasimo SET®パルスオキシメトリーを使用するホームモニタリングの有用性を検討する新研究